Alex Therapeutics
About Alex Therapeutics
Alex Therapeutics is a digital health company founded in 2018 by John Drakenberg and Oliver Fleetwood. The company partners with pharma to support people with treatment and disease-related mental health challenges through clinically validated companion apps.
They specialize in oncology and rare diseases, which typically involve complex treatment regimes and emotional distress. Their mission is to create clinically validated digital tools that address the unique challenges of disease and treatment-specific management, ensuring individuals have the support they need to live more confidently and thrive.
What They Do
Alex Therapeutics creates companion apps to help patients manage their treatments and mental health challenges, leading to improved patient outcomes.
They develop Software as a Medical Device (SaMD) products, which have been clinically proven to benefit patients across various indications.
They develop Software as a Medical Device (SaMD) products, which have been clinically proven to benefit patients across various indications.
Their technology platform enables pharma companies to launch indication-specific companion digital health solutions at scale, focusing on oncology and rare diseases with high mental health comorbidity.
Alex Therapeutics is ISO 27001 certified and ensures compliance with EU MDR and FDA requirements for global market readiness.